Novo Nordisk A/S: Novo Nordisk completes phase 3a trials comparing faster-acting insulin aspart with NovoRapid® in people with type 1 and type 2 diabetes
(Thomson Reuters ONE) -
Bagsværd, Denmark, 25 March 2015 - Novo Nordisk today announced headline results
from the final phase 3a trials for faster-acting insulin aspart, onset(® )1 and
onset(® )2. The trials investigated the efficacy and safety of faster-acting
insulin aspart compared with NovoRapid(®) (insulin aspart) in a basal-bolus
regimen in people with type 1 and type 2 diabetes, respectively.
For further information
Media:
Mike Rulis +45 3079 3573 mike(at)novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau(at)novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop(at)novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz(at)novonordisk.com
Daniel Bohsen +45 3079 6376 dabo(at)novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni(at)novonordisk.com
Company Announcement No 22 2015
Company Announcement No 22 2015:
http://hugin.info/2013/R/1906174/678581.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via GlobeNewswire
[HUG#1906174]
Unternehmensinformation / Kurzprofil:
Datum: 25.03.2015 - 18:15 Uhr
Sprache: Deutsch
News-ID 381131
Anzahl Zeichen: 1661
contact information:
Town:
Bagsvaerd
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 172 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novo Nordisk A/S: Novo Nordisk completes phase 3a trials comparing faster-acting insulin aspart with NovoRapid® in people with type 1 and type 2 diabetes"
steht unter der journalistisch-redaktionellen Verantwortung von
Novo Nordisk A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
